Moderna, Inc. is a U.S.-based biotechnology company focused on the discovery, development, and manufacturing of messenger RNA (mRNA) therapeutics and vaccines. Founded in 2010 and headquartered in Cambridge, Massachusetts, the company’s platform enables rapid design and production of mRNA drug substances and lipid nanoparticle (LNP)–formulated products. Its portfolio spans infectious diseases, oncology, and rare diseases, and includes Spikevax (mRNA-1273), an approved COVID-19 vaccine in multiple regions.
From a chemistry and manufacturing perspective, Moderna integrates nucleotide and enzymatic synthesis (in vitro transcription), sequence and cap modifications, and downstream purification with sterile formulation and fill–finish. Its LNP systems typically combine ionizable lipids, phospholipids, cholesterol, and PEGylated lipids to protect and deliver mRNA, relying on tightly controlled excipient quality and process parameters. The company operates and partners across a global cGMP network for clinical and commercial supply, emphasizing modular, scalable production and rigorous cold-chain logistics. Moderna’s activities sit at the intersection of advanced biologics and materials science, with implications for suppliers of specialty lipids, polymers, enzymes, nucleotides, single-use systems, and analytical technologies.